DekaBank Deutsche Girozentrale Has $1.64 Million Stock Position in Charles River Laboratories International, Inc. (NYSE:CRL)

DekaBank Deutsche Girozentrale boosted its holdings in Charles River Laboratories International, Inc. (NYSE:CRL) by 12.0% during the 2nd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 7,906 shares of the medical research company’s stock after acquiring an additional 850 shares during the quarter. DekaBank Deutsche Girozentrale’s holdings in Charles River Laboratories International were worth $1,640,000 at the end of the most recent quarter.

A number of other hedge funds have also added to or reduced their stakes in CRL. Vanguard Group Inc. raised its stake in shares of Charles River Laboratories International by 1.1% in the first quarter. Vanguard Group Inc. now owns 6,046,467 shares of the medical research company’s stock worth $1,638,290,000 after purchasing an additional 66,161 shares during the last quarter. Clearbridge Investments LLC lifted its stake in Charles River Laboratories International by 3.1% during the 1st quarter. Clearbridge Investments LLC now owns 1,513,138 shares of the medical research company’s stock valued at $409,985,000 after acquiring an additional 45,079 shares in the last quarter. Allspring Global Investments Holdings LLC boosted its holdings in Charles River Laboratories International by 11.9% during the 2nd quarter. Allspring Global Investments Holdings LLC now owns 1,251,618 shares of the medical research company’s stock worth $258,559,000 after acquiring an additional 132,802 shares during the last quarter. Meritage Group LP boosted its holdings in Charles River Laboratories International by 2.3% during the 1st quarter. Meritage Group LP now owns 1,182,268 shares of the medical research company’s stock worth $320,336,000 after acquiring an additional 26,892 shares during the last quarter. Finally, Earnest Partners LLC grew its stake in shares of Charles River Laboratories International by 0.5% in the 1st quarter. Earnest Partners LLC now owns 893,761 shares of the medical research company’s stock worth $242,165,000 after acquiring an additional 4,393 shares in the last quarter. Institutional investors and hedge funds own 98.91% of the company’s stock.

Charles River Laboratories International Price Performance

Charles River Laboratories International stock opened at $209.42 on Friday. The firm has a market capitalization of $10.79 billion, a P/E ratio of 24.66, a PEG ratio of 3.89 and a beta of 1.36. Charles River Laboratories International, Inc. has a one year low of $161.65 and a one year high of $275.00. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.58 and a quick ratio of 1.21. The business has a fifty day moving average price of $209.57 and a 200-day moving average price of $224.53.

Charles River Laboratories International (NYSE:CRL) last issued its earnings results on Wednesday, August 7th. The medical research company reported $2.80 EPS for the quarter, topping the consensus estimate of $2.39 by $0.41. Charles River Laboratories International had a return on equity of 14.96% and a net margin of 10.83%. The business had revenue of $1.03 billion during the quarter, compared to the consensus estimate of $1.03 billion. As a group, equities research analysts forecast that Charles River Laboratories International, Inc. will post 10.01 EPS for the current year.

Charles River Laboratories International announced that its board has authorized a share buyback program on Wednesday, August 7th that permits the company to buyback $1.00 billion in outstanding shares. This buyback authorization permits the medical research company to reacquire up to 9.6% of its shares through open market purchases. Shares buyback programs are often a sign that the company’s management believes its stock is undervalued.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on CRL. Evercore ISI cut their price target on shares of Charles River Laboratories International from $265.00 to $225.00 and set an “outperform” rating on the stock in a report on Thursday, August 8th. The Goldman Sachs Group cut their target price on Charles River Laboratories International from $290.00 to $250.00 and set a “buy” rating on the stock in a research note on Thursday, August 8th. StockNews.com raised Charles River Laboratories International from a “hold” rating to a “buy” rating in a research report on Tuesday, August 20th. Argus reissued a “hold” rating on shares of Charles River Laboratories International in a research report on Friday, June 28th. Finally, TD Cowen decreased their target price on Charles River Laboratories International from $228.00 to $203.00 and set a “hold” rating for the company in a research report on Monday, August 12th. Ten investment analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $231.00.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).